Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-01 dwell-time study in overt hepatic encephalopathy
2025-521029-34-00Phase 2Completed
- Sponsor
- Versantis AG
- Start
- Sep 2025
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of VS-01-HAC in hepatic encephalopathy (HE), Cirrhosis, acute-on-chronic liver failure (ACLF) and 1 more (3 arms), sponsored by Versantis AG. Primary endpoint: Time to improvement of overt hepatic encephalopathy. Started Sep 2025; status: completed.
02
Drugs
VS-01-HAC
03
Conditions
hepatic encephalopathy (HE)Cirrhosisacute-on-chronic liver failure (ACLF)ascites
Beyond the preview
Go deeper on 2025-521029-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521029-34-00.